In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma

Whereas TLR9 agonists are recognized as powerful stimulators of antitumor immunity, GM-CSF has had mixed reviews. In previously reported randomized trials we assessed the effects of local immune modulation in early-stage melanoma with CpG-B alone or with GM-CSF. Here we discuss the added value of GM...

Descripción completa

Detalles Bibliográficos
Autores principales: Koster, Bas D., de Jong, Tamarah D., van den Hout, Mari F. C. M., Sluijter, Berbel J. R., Vuylsteke, Ronald J. C. L. M., Molenkamp, Barbara G., Vosslamber, Saskia, van den Tol, M. Petrousjka, van den Eertwegh, Alfons J. M., de Gruijl, Tanja D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Point-of-View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959435/
https://www.ncbi.nlm.nih.gov/pubmed/32002303
http://dx.doi.org/10.1080/2162402X.2019.1708066
Descripción
Sumario:Whereas TLR9 agonists are recognized as powerful stimulators of antitumor immunity, GM-CSF has had mixed reviews. In previously reported randomized trials we assessed the effects of local immune modulation in early-stage melanoma with CpG-B alone or with GM-CSF. Here we discuss the added value of GM-CSF and show sex-related differences.

Ejemplares similares